Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis.

ABSTRACT

BACKGROUND: It has been suggested that serum leucine-rich α-2 glycoprotein (LRG) could be a novel monitoring biomarker for the assessment of disease activity in inflammatory bowel disease. In particular, the relationship between LRG levels and the endoscopically assessed activity of ulcerative colitis (UC) has become a matter of interest. AIM: To clarify appropriate LRG cut-off values for the prediction of endoscopic and histologic remission in Japanese patients with UC. METHODS: This was a cross-sectional, single-center, observational study of Japanese patients with UC. Among 213 patients with UC, in whom LRG was measured from September 2020 to February 2022, we recruited 30 patients for whom a total colonoscopy and measurements of LRG and C-reactive protein (CRP) were performed on the same day. We retrospectively analyzed correlations between the LRG and CRP levels and endoscopic indices, including the Mayo endoscopic subscore and UC endoscopic index of severity. RESULTS: Correlations between the LRG values and the Mayo endoscopic subscore or UC endoscopic index of severity were significant (r = 0.754, P < 0.0001; r = 0.778, P < 0.0001, respectively). There were also significant correlations between CRP levels and Mayo endoscopic subscore or UC endoscopic index of severity (r = 0.599, P = 0.0005; r = 0.563, P = 0.0012, respectively), although the correlation coefficients were higher for LRG. The LRG cut-off value for predicting endoscopic remission was 13.4 µg/mL for a Mayo endoscopic subscore of 0 [area under the curve (AUC) 0.871; 95% confidence interval (CI) 0.744-0.998], and 13.4 µg/mL for an UC endoscopic index of severity of 0 or 1 (AUC 0.904; 95%CI 0.792-1.000). CONCLUSION: LRG may be a surrogate marker for endoscopic activity in UC, with a cut-off value of around 13.4 µg/mL for endoscopically inactive disease.